New drug cocktail targets aggressive breast cancer
NCT ID NCT05230810
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a combination of two targeted drugs, tucatinib and alpelisib, in people with a specific genetic mutation (PIK3CA) and HER2-positive advanced breast cancer. About 40 adults whose cancer has spread or cannot be removed will take these pills daily. The goal is to see if the combo is safe and can slow cancer growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tucatinib and alpelisib (targeted cancer pills), plus fulvestrant (injection) for some patients
What this could lead to
If it works, this could offer a new treatment option for people with a hard-to-treat form of advanced breast cancer.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply widely. The drug combination may cause side effects or fail to slow the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Care & Hematology-Fort Collins
Fort Collins, Colorado, 80528, United States
-
Louisiana State University Health Sciences Center
New Orleans, Louisiana, 70112, United States
-
University of Colorado Cancer Center
Aurora, Colorado, 80045, United States
-
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin, 53792, United States